Scandion Oncology Q2 2024: Partnership represents best hope - Redeye

Redeye comments on Scandion Oncology’s Q2 2024 report, shortly after the company announced that its CORIST part 3 extension trial reached MTD. The company has intensified its partnering outreach, and we judge a potential partnership or similar is its best hope of advancing SCO-101’s clinical development. Scandion raised gross proceeds of cDKK20.0m through its recent rights issue, while issue-related expenses amounted to cDKK5.9m or c30% of gross proceeds. We adjust our estimates and do some housekeeping in our model.

Länk till analysen i sin helhet: https://www.redeye.se/research/1036592/scandion-oncology-q2-2024-partnership-represents-best-hope?utm_source=finwire&utm_medium=RSS